Cost-effectiveness analysis of treatment of methicillin-resistant Staphylococcus aureus bacteremia and endocarditis is a difficult issue.
Westling
Katarina
K
D000900:Anti-Bacterial Agents / Q000191:economics* / Q000627:therapeutic use*; D016470:Bacteremia / Q000188:drug therapy / Q000191:economics / Q000382:microbiology; D002408:Catheters, Indwelling / Q000382:microbiology; D003362:Cost-Benefit Analysis; D003428:Cross Infection / Q000188:drug therapy / Q000191:economics / Q000382:microbiology; D004697:Endocarditis, Bacterial / Q000188:drug therapy / Q000191:economics / Q000382:microbiology; D006801:Humans; D055624:Methicillin-Resistant Staphylococcus aureus; D008826:Microbial Sensitivity Tests; D013203:Staphylococcal Infections / Q000188:drug therapy* / Q000191:economics* / Q000382:microbiology; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents